HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daniel Gusenleitner Selected Research

spartalizumab

1/2022Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
1/2022Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
10/2020Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Daniel Gusenleitner Research Topics

Disease

11Neoplasms (Cancer)
01/2022 - 02/2011
7Melanoma (Melanoma, Malignant)
01/2022 - 01/2018
2Breast Neoplasms (Breast Cancer)
11/2016 - 06/2015
1Inflammation (Inflammations)
01/2022
1Hodgkin Disease (Hodgkin's Disease)
11/2017
1Neoplasm Metastasis (Metastasis)
11/2016
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2016

Drug/Important Bio-Agent (IBA)

5Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2018
4dabrafenibIBA
01/2022 - 01/2020
4trametinibIBA
01/2022 - 01/2020
3spartalizumabIBA
01/2022 - 10/2020
3Immune Checkpoint InhibitorsIBA
01/2021 - 01/2018
2DNA (Deoxyribonucleic Acid)IBA
01/2022 - 02/2011
2RNA (Ribonucleic Acid)IBA
01/2022 - 01/2015
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 10/2020
2Proteins (Proteins, Gene)FDA Link
01/2018 - 01/2018
2Programmed Cell Death 1 ReceptorIBA
01/2018 - 11/2017
2LigandsIBA
11/2017 - 11/2016
2Biological ProductsIBA
11/2016 - 01/2016
1Circulating Tumor DNAIBA
01/2022
1B7-H1 AntigenIBA
01/2022
1HLA-A Antigens (HLA-A)IBA
01/2018
1AntigensIBA
01/2018
1InterferonsIBA
01/2018
1Ligases (Synthetase)IBA
01/2018
1HLA-B Antigens (HLA-B)IBA
01/2018
1HLA-C Antigens (HLA-C)IBA
01/2018
1UbiquitinIBA
01/2018
1CTLA-4 AntigenIBA
01/2018
1Tryptophan (L-Tryptophan)FDA Link
11/2016
1Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA
11/2016
1EnzymesIBA
11/2016
1xanthurenic acidIBA
11/2016
1Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
11/2016
1KynurenineIBA
11/2016
16- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA
01/2016
1B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA
01/2016
1Syk KinaseIBA
01/2016
1CarcinogensIBA
06/2015
1ParaffinIBA
01/2015
1Formaldehyde (Formol)FDA Link
01/2015

Therapy/Procedure

6Therapeutics
01/2022 - 01/2018
1Immunotherapy
01/2018